Welcome to our dedicated page for Oscar Health news (Ticker: OSCR), a resource for investors and traders seeking the latest updates and insights on Oscar Health stock.
Oscar Health, Inc. (NYSE: OSCR) generates a steady flow of news as a healthcare technology company that combines Individual & Family health insurance plans with a full stack technology platform. Company press releases frequently highlight new market entries, specialized plan designs, and technology-driven member support tools, making OSCR news relevant for investors and observers of the health insurance and digital health sectors.
Much of Oscar’s recent news focuses on the expansion of its affordable, tech-powered health plans across U.S. regions. The company has announced new offerings for individuals, families, and businesses in areas such as Southern Florida, the Tampa Bay area, Orlando and Central Florida, Charlotte and surrounding North Carolina markets, Columbus in Ohio, the Dallas/Fort Worth region in Texas, and multiple counties in Arizona. These announcements detail the availability of Bronze, Silver, Gold, and Redesigned Gold plans, as well as specialized options like HelloMeno menopause plans, condition-focused plans for chronic conditions, Guided Care HMO products, and Spanish-first diabetes plans.
Oscar’s news also covers partnerships and employer-focused initiatives. For example, the Hy-Vee Health with Oscar plan in the Des Moines business community showcases an employer-funded individual market arrangement using an ICHRA structure, combining health coverage, concierge-style care, and lifestyle rewards. In addition, many releases emphasize the role of Oswell, Oscar’s personal health AI agent, and Oscar Care Guides in providing on-demand support and navigation for members.
Investors following OSCR news will also find updates on financial performance and capital structure in the company’s earnings announcements and related Form 8-K filings. These communications include quarterly results, membership metrics, guidance updates, and details on convertible note offerings and exchange agreements. For ongoing insight into how Oscar is expanding its footprint, refining its technology platform, and managing its financial profile, this news feed provides a centralized view of the company’s public disclosures.
Oscar Health (NYSE: OSCR) is launching individual, family, and small‑business health plans in Alabama for 2026 Open Enrollment.
Plans will be available in Jefferson, Limestone, Madison, Shelby, and Walker counties with an effective date of Jan. 1, 2026. Enrollment for individuals, families, and ICHRA employer-funded employees begins Nov. 1, 2025. Offerings include Bronze, Silver, and Gold tiers, a Chronic Care Plan that advertises members can save up to $800 a year, $0 virtual urgent care, $0 primary and specialty visits in the Chronic Care Plan, an AI personal health agent called Oswell, and a digital rewards program Oscar Unlocks.
Oscar (NYSE: OSCR) and Elektra Health launched HelloMeno, the first menopause-focused ACA individual-market health plan, announced Oct 20, 2025.
The plan targets an estimated 2.3 million women aged 45+ in the ACA, offers up to $900 in annual savings, $0 primary care, gynecology, and behavioral visits, no-cost labs, hormone replacement therapy, insomnia meds, bone density scans, and up to $120 in preventive-screening rewards.
Open enrollment runs Nov 1, 2025–Jan 15, 2026; coverage effective Jan 1, 2026. Initial availability: Arizona, Florida, Georgia, Iowa, Missouri, Nebraska, North Carolina, Ohio, Oklahoma, Tennessee, and Texas. More information at hioscar.com/hellomeno.
Oscar Health (NYSE: OSCR) announced 2026 individual-market expansions and new member features for open enrollment starting Nov. 1, 2025 for certain groups. The Oscar experience will be offered in 573 counties across 20 states, including new entry into Alabama and Mississippi.
Key product launches include Oswell, a personal AI agent powered by OpenAI that accesses records, benefits, and care guides to assist members and connect them to $0 virtual care; HelloMeno, a menopause plan with $0 primary, gyne, and behavioral visits and estimated savings of ~$900/year; and expanded clinical plans for chronic conditions with estimated savings of ~$800/year. Oscar also introduced a digital rewards program, Hola Oscar for Hispanic and Latino members, and the Hy-Vee Health with Oscar employer plan in Des Moines.
Oscar Health (NYSE: OSCR) will release its Q3 2025 financial results before the market opens on Thursday, November 6, 2025. Management will discuss results on a conference call starting at 8:00 AM ET.
Investors can join by phone at 1.855.761.5600 (Conference ID: 7768132) or listen via webcast. The webcast will be archived on the company's investor relations site for 90 days after November 6, 2025.
Oscar Health (NYSE:OSCR) has successfully priced an upsized offering of $355 million in convertible senior subordinated notes due 2030, with a 2.25% interest rate. The offering, increased from the initially announced $350 million, includes an option for purchasers to buy an additional $55 million in notes.
The notes will convert at an initial rate of 40.2946 shares per $1,000 principal amount, representing a conversion price of $24.82 per share - a 32.5% premium over the last closing price. To mitigate dilution, Oscar entered into capped call transactions with a cap price of $37.46 per share.
Net proceeds of approximately $342.5 million will support general corporate purposes, including AI initiatives, healthcare experience enhancement, and potential premium tax credit extensions. The company will also terminate its existing revolving credit facility upon the offering's closing.
Oscar Health (NYSE:OSCR) has announced plans to offer $350 million in convertible senior subordinated notes due 2030, with an additional option for purchasers to buy up to $52.5 million in notes. The offering aims to support general corporate purposes, including AI initiatives, healthcare cost reduction, and enhanced consumer experiences.
The notes will be convertible to cash, class A common stock, or a combination thereof. To mitigate potential dilution, Oscar will enter into capped call transactions. The company plans to terminate its existing revolving credit facility upon the offering's closing. The notes will be redeemable after September 6, 2028, if Oscar's stock price exceeds 130% of the conversion price for a specified period.
Oscar Health (NYSE:OSCR) and Hy-Vee have announced a strategic partnership to launch Hy-Vee Health with Oscar, an innovative employer healthcare benefit program. The initiative will debut in Des Moines, Iowa, targeting approximately 400,000 employees through the individual marketplace starting November 1, 2025.
The program offers significant cost savings, with businesses potentially saving 20% to 30% and employees saving $500 to $1,000 annually. Key benefits include $0 care at Hy-Vee Health Exemplar Care clinics, access to MercyOne specialists, affordable prescriptions at Hy-Vee pharmacies, dedicated Oscar Care Guides, and Hy-Vee rewards for grocery savings.
Oscar Health (NYSE:OSCR) reported its Q2 2025 financial results, showing significant revenue growth but facing profitability challenges. Total revenue reached $2.9 billion, up from $2.2 billion in Q2 2024, driven by increased membership to 2.02 million members.
The company reported a net loss of $228.4 million ($0.89 per share) compared to a net income of $56.2 million in Q2 2024. The medical loss ratio increased to 91.1% from 79.0%, while the SG&A expense ratio improved to 18.7% from 19.6%. Management expects market stabilization in 2026 and anticipates a return to profitability, viewing the individual market as having long-term growth potential.
Oscar Health (NYSE:OSCR) released preliminary Q2 2025 results and revised its 2025 guidance downward. The company expects a Q2 2025 operating loss of $230 million and a net loss of $228 million. The revision follows analysis of 2025 Marketplace data showing higher-than-expected ACA Marketplace risk scores.
For full year 2025, Oscar now projects total revenue of $12.0-12.2 billion, a medical loss ratio of 86.0-87.0%, and an SG&A expense ratio of 17.1-17.6%. The company anticipates a loss from operations between $300 million and $200 million. In response, Oscar plans to resubmit 2026 rate filings for approximately 98% of current membership to reflect higher market risk scores.